- Eli Lilly And Co (NYSE:LLY) said it would continue to supply drugs to Russia for urgent medical conditions such as cancer and diabetes but will suspend sales of "non-essential medicines."
- Lilly also suspended investments and promotion activities in Russia and will not start any new clinical trials in the country.
- With several Western companies leaving Russia, drugmakers and medical-device firms have also said they will stop investments and new clinical trials in the country but will continue to provide medicines to patients for humanitarian reasons.
- As per Reuters, Lilly is the first to exclude drugs it designates as "non-essential," It did not disclose specific treatments affected by the decision.
- On Monday, Pfizer Inc (NYSE:PFE), Bayer AG (OTC:BAYRY), and Abbott Laboratories (NYSE:ABT) said that they have pulled back from non-essential spending in Russia.
- Related: Pfizer To Stop New Clinical Trials In Russia: Reuters.
- Lilly said any profit from continued sales in Russia would be donated to organizations dedicated to humanitarian relief.
- Price Action: LLY shares are up 2.44% at $275.58 during the market session on the last check Tuesday.
Get all your news in one place.
100’s of premium titles.
One app.
Start reading
One app.
Get all your news in one place.
100’s of premium titles. One news app.
Eli Lilly To Suspend Sale Of 'Non-Essential' Medicines To Russia
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member?
Sign in here
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member?
Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member?
Sign in here
Our Picks